BEST OF ONCOLOGY WEST 2024: Gynecological Cancers – Dr. Anna Tinker
OR
Chair
Dr. Sharlene Gill
Dr. Daniel Heng
Panelist
Dr. Anna Tinker
Studies/trials discussed:
- Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
- Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
- Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
- AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer
- Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
- A clinically applicable molecular-based classification for endometrial cancers
- Clinical and Biological Activity of Check for updates Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium
- ENGOT-EN6/NSGO-RUBY: A phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC)
- Memory and other properties of multiple test procedures generated by entangled graphs
- Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
